{"transactions":[{"id":917267,"issuer":{"id":1907,"kind":"organization","name":"Veradermics, Inc","symbol":"MANE"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Commercial Officer","other_text":"Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T19:02:00.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":102885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service."}],"balance_after":102885,"derivative":{"exercise_price":17,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":102885},"source":{"system":"sec-edgar","filing":"0001628280-26-005900","document":"wk-form4_1770336117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756211/000162828026005900/wk-form4_1770336117.xml","form_type":"4"}},{"id":1182640,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8742},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182639,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":8742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":8742,"derivative":{"underlying":"Common Stock","underlying_shares":8742},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182638,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13134,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13134},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182637,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":13134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":13134,"derivative":{"underlying":"Common Stock","underlying_shares":13134},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182636,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22727,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182635,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17485,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17485},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182634,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13133,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13133},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182633,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17916,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":56.73,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":17916},"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1182632,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-04-02T17:41:07.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52811,"price":132,"value":6971052.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-049627","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049627/ownership.xml","form_type":"4"}},{"id":1214514,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-10T18:01:04.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":false,"shares":7345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7345},"source":{"system":"sec-edgar","filing":"0000950170-25-036592","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036592/ownership.xml","form_type":"4"}},{"id":1214513,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-10T18:01:04.000Z","date":"2025-03-06","kind":"exercise","planned":false,"acquired":false,"shares":13133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":13133,"derivative":{"underlying":"Common Stock","underlying_shares":13133},"source":{"system":"sec-edgar","filing":"0000950170-25-036592","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036592/ownership.xml","form_type":"4"}},{"id":1214512,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:04.000Z","date":"2025-03-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3116,"price":131.24,"value":408943.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person."}],"balance_after":52811,"source":{"system":"sec-edgar","filing":"0000950170-25-036592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036592/ownership.xml","form_type":"4"}},{"id":1214511,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:04.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":true,"shares":7345,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":55927,"source":{"system":"sec-edgar","filing":"0000950170-25-036592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036592/ownership.xml","form_type":"4"}},{"id":1214510,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:04.000Z","date":"2025-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":5572,"price":131.19,"value":730990.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person."}],"balance_after":48582,"source":{"system":"sec-edgar","filing":"0000950170-25-036592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036592/ownership.xml","form_type":"4"}},{"id":1214509,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:04.000Z","date":"2025-03-06","kind":"exercise","planned":false,"acquired":true,"shares":13133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":54154,"source":{"system":"sec-edgar","filing":"0000950170-25-036592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036592/ownership.xml","form_type":"4"}},{"id":1226535,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T18:01:06.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":8742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":17485,"derivative":{"underlying":"Common Stock","underlying_shares":8742},"source":{"system":"sec-edgar","filing":"0000950170-25-032585","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025032585/ownership.xml","form_type":"4"}},{"id":1226534,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T18:01:06.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3709,"price":128.2,"value":475493.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person."}],"balance_after":41021,"source":{"system":"sec-edgar","filing":"0000950170-25-032585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025032585/ownership.xml","form_type":"4"}},{"id":1226533,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T18:01:06.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":8742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":44730,"source":{"system":"sec-edgar","filing":"0000950170-25-032585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025032585/ownership.xml","form_type":"4"}},{"id":1283806,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T17:31:20.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":22727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 3, 2025, the reporting person was granted 22,727 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 3, 2025, the reporting person was granted 22,727 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":22727,"derivative":{"underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0000950170-25-013762","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025013762/ownership.xml","form_type":"4"}},{"id":1283805,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T17:31:20.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4729,"price":127,"value":600583.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the reporting person."}],"balance_after":35988,"source":{"system":"sec-edgar","filing":"0000950170-25-013762","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025013762/ownership.xml","form_type":"4"}},{"id":1283804,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T17:31:20.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":11017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 10, 2022, the reporting person was granted performance-based restricted stock units (\"PRSUs\") under the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan. Each PRSU represents a contingent right to receive one share of common stock upon vesting and settlement. On January 31, 2025, 11,017 PRSUs were vested upon achievement of the reporting person's performance criteria."}],"balance_after":40717,"source":{"system":"sec-edgar","filing":"0000950170-25-013762","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025013762/ownership.xml","form_type":"4"}},{"id":1427358,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-20T18:03:54.000Z","date":"2024-08-16","kind":"exercise","planned":false,"acquired":false,"shares":18714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":36.89,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":18714},"source":{"system":"sec-edgar","filing":"0000950170-24-099258","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/ownership.xml","form_type":"4"}},{"id":1427357,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-08-20T18:03:54.000Z","date":"2024-08-16","kind":"sale","planned":false,"acquired":false,"shares":18714,"price":75.08,"value":1405047.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29700,"source":{"system":"sec-edgar","filing":"0000950170-24-099258","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/ownership.xml","form_type":"4"}},{"id":1427356,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-08-20T18:03:54.000Z","date":"2024-08-16","kind":"exercise","planned":false,"acquired":true,"shares":18714,"price":36.89,"value":690359.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 16, 2024, the reporting person exercised options to purchase 18,714 shares of common stock."}],"balance_after":48414,"source":{"system":"sec-edgar","filing":"0000950170-24-099258","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/ownership.xml","form_type":"4"}},{"id":1583617,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-10","kind":"exercise","planned":true,"acquired":false,"shares":7345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":7345,"derivative":{"underlying":"Common Stock","underlying_shares":7345},"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1583616,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1313,"price":66.86,"value":87787.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.69 to $67.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29700,"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1583615,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1729,"price":65.92,"value":113975.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.58 to $66.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":31013,"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1583614,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":4303,"price":65.11,"value":280168.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.57 to $65.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":32742,"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1583613,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-10","kind":"exercise","planned":true,"acquired":true,"shares":7345,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":37045,"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1583612,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":4496,"price":66.95,"value":301007.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.7827 to $67.1038, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29700,"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1583611,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T20:31:47.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":8636,"price":66.37,"value":573171.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.765 to $66.7624, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":34196,"source":{"system":"sec-edgar","filing":"0000950170-24-029580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029580/ownership.xml","form_type":"4"}},{"id":1586037,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-08T17:59:18.000Z","date":"2024-03-06","kind":"exercise","planned":false,"acquired":false,"shares":13132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":26266,"derivative":{"underlying":"Common Stock","underlying_shares":13132},"source":{"system":"sec-edgar","filing":"0000950170-24-028823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024028823/ownership.xml","form_type":"4"}},{"id":1586036,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-08T17:59:18.000Z","date":"2024-03-06","kind":"exercise","planned":false,"acquired":true,"shares":13132,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":42832,"source":{"system":"sec-edgar","filing":"0000950170-24-028823","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024028823/ownership.xml","form_type":"4"}},{"id":1594245,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T19:05:00.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":26227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":26227,"derivative":{"underlying":"Common Stock","underlying_shares":26227},"source":{"system":"sec-edgar","filing":"0000950170-24-026537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024026537/ownership.xml","form_type":"4"}},{"id":1614616,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-27T19:58:07.000Z","date":"2024-02-23","kind":"exercise","planned":true,"acquired":false,"shares":7907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7907},"source":{"system":"sec-edgar","filing":"0000950170-24-021564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021564/ownership.xml","form_type":"4"}},{"id":1614615,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-27T19:58:07.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":1307,"price":71.18,"value":93032.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.12 to $71.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29700,"source":{"system":"sec-edgar","filing":"0000950170-24-021564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021564/ownership.xml","form_type":"4"}},{"id":1614614,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-27T19:58:07.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":2341,"price":70.7,"value":165508.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.105, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":31007,"source":{"system":"sec-edgar","filing":"0000950170-24-021564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021564/ownership.xml","form_type":"4"}},{"id":1614613,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-27T19:58:07.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":4059,"price":69.56,"value":282344.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.11 to $70.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":33348,"source":{"system":"sec-edgar","filing":"0000950170-24-021564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021564/ownership.xml","form_type":"4"}},{"id":1614612,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-27T19:58:07.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":200,"price":68.03,"value":13606.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.70 to $68.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":37407,"source":{"system":"sec-edgar","filing":"0000950170-24-021564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021564/ownership.xml","form_type":"4"}},{"id":1614611,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-27T19:58:07.000Z","date":"2024-02-23","kind":"exercise","planned":true,"acquired":true,"shares":7907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":37607,"source":{"system":"sec-edgar","filing":"0000950170-24-021564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021564/ownership.xml","form_type":"4"}},{"id":1658200,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-05T18:07:48.000Z","date":"2024-02-02","kind":"sale","planned":true,"acquired":false,"shares":6904,"price":67.49,"value":465950.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to\ncover the reporting person's tax liability arising from the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.16 to $68.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29700,"source":{"system":"sec-edgar","filing":"0000950170-24-011394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024011394/ownership.xml","form_type":"4"}},{"id":1658199,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-05T18:07:48.000Z","date":"2024-02-02","kind":"sale","planned":true,"acquired":false,"shares":4956,"price":66.67,"value":330416.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to\ncover the reporting person's tax liability arising from the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.1 to $67.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":36604,"source":{"system":"sec-edgar","filing":"0000950170-24-011394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024011394/ownership.xml","form_type":"4"}},{"id":1658198,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-05T18:07:48.000Z","date":"2024-02-01","kind":"grant","planned":true,"acquired":true,"shares":11860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issued upon the vesting of performance stock units."}],"balance_after":41560,"source":{"system":"sec-edgar","filing":"0000950170-24-011394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024011394/ownership.xml","form_type":"4"}},{"id":1746537,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-08T17:31:41.000Z","date":"2023-11-06","kind":"exercise","planned":false,"acquired":false,"shares":26754,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":23.94,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":26754},"source":{"system":"sec-edgar","filing":"0001209191-23-054726","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123054726/doc4.xml","form_type":"4"}},{"id":1746536,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-08T17:31:41.000Z","date":"2023-11-06","kind":"sale","planned":false,"acquired":false,"shares":15639,"price":55.0174,"value":860417.1186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.76 to $55.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29700,"source":{"system":"sec-edgar","filing":"0001209191-23-054726","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123054726/doc4.xml","form_type":"4"}},{"id":1746535,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-08T17:31:41.000Z","date":"2023-11-06","kind":"sale","planned":false,"acquired":false,"shares":26754,"price":55.9817,"value":1497734.4018,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.79 to $56.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-23-054726","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123054726/doc4.xml","form_type":"4"}},{"id":1746534,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-08T17:31:41.000Z","date":"2023-11-06","kind":"exercise","planned":false,"acquired":true,"shares":26754,"price":23.94,"value":640490.76,"ownership":{"direct":true},"balance_after":72093,"source":{"system":"sec-edgar","filing":"0001209191-23-054726","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123054726/doc4.xml","form_type":"4"}},{"id":1811714,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-09T18:05:36.000Z","date":"2023-08-07","kind":"exercise","planned":false,"acquired":false,"shares":55300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":18.59,"expiration_date":"2028-10-14","underlying":"Common Stock","underlying_shares":55300},"source":{"system":"sec-edgar","filing":"0001209191-23-045229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123045229/doc4.xml","form_type":"4"}},{"id":1811713,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-08-09T18:05:36.000Z","date":"2023-08-07","kind":"sale","planned":false,"acquired":false,"shares":55300,"price":58.79,"value":3251087.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.3319 to $59.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-23-045229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123045229/doc4.xml","form_type":"4"}},{"id":1811712,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-08-09T18:05:36.000Z","date":"2023-08-07","kind":"exercise","planned":false,"acquired":true,"shares":55300,"price":18.59,"value":1028027.0,"ownership":{"direct":true},"balance_after":100639,"source":{"system":"sec-edgar","filing":"0001209191-23-045229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123045229/doc4.xml","form_type":"4"}},{"id":1934793,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-30T17:08:31.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":10183,"price":54.01,"value":549983.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.950 to $54.050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-23-021627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123021627/doc4.xml","form_type":"4"}},{"id":1934792,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-30T17:08:31.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":5421,"price":54.86,"value":297396.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.070 to $55.045, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":55522,"source":{"system":"sec-edgar","filing":"0001209191-23-021627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123021627/doc4.xml","form_type":"4"}},{"id":1956364,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":7344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":14690,"derivative":{"underlying":"Common Stock","underlying_shares":7344},"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1956363,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":423,"price":44.05,"value":18633.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":60943,"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1956362,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":3335,"price":45.1,"value":150408.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.79 to $45.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":61366,"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1956361,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":7344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":64701,"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1956360,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-10","kind":"sale","acquired":false,"shares":1800,"price":42.74,"value":76932.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.15 to $43.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":57357,"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1956359,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-10","kind":"sale","acquired":false,"shares":6750,"price":43.5,"value":293625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":59157,"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1956358,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T19:35:04.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":16708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issued upon the vesting of performance stock units."}],"balance_after":65907,"source":{"system":"sec-edgar","filing":"0001209191-23-018286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123018286/doc4.xml","form_type":"4"}},{"id":1962607,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-08T19:52:56.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":39398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":39398,"derivative":{"underlying":"Common Stock","underlying_shares":39398},"source":{"system":"sec-edgar","filing":"0001209191-23-017373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123017373/doc4.xml","form_type":"4"}},{"id":1971796,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T19:03:35.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":7241,"price":50.01,"value":362122.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.495, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":49199,"source":{"system":"sec-edgar","filing":"0001209191-23-016024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123016024/doc4.xml","form_type":"4"}},{"id":1989737,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-27T20:03:12.000Z","date":"2023-02-23","kind":"exercise","acquired":false,"shares":7906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":7907,"derivative":{"underlying":"Common Stock","underlying_shares":7906},"source":{"system":"sec-edgar","filing":"0001209191-23-013442","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123013442/doc4.xml","form_type":"4"}},{"id":1989736,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-27T20:03:12.000Z","date":"2023-02-24","kind":"sale","acquired":false,"shares":4046,"price":47.12,"value":190647.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.88 to $47.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":56440,"source":{"system":"sec-edgar","filing":"0001209191-23-013442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123013442/doc4.xml","form_type":"4"}},{"id":1989735,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-27T20:03:12.000Z","date":"2023-02-23","kind":"exercise","acquired":true,"shares":7906,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":60486,"source":{"system":"sec-edgar","filing":"0001209191-23-013442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123013442/doc4.xml","form_type":"4"}},{"id":1998809,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-22T20:05:55.000Z","date":"2023-02-18","kind":"exercise","acquired":false,"shares":11139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11139},"source":{"system":"sec-edgar","filing":"0001209191-23-012001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123012001/doc4.xml","form_type":"4"}},{"id":1998808,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-22T20:05:55.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":635,"price":48.93,"value":31070.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.77 to $49.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":52580,"source":{"system":"sec-edgar","filing":"0001209191-23-012001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123012001/doc4.xml","form_type":"4"}},{"id":1998807,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-22T20:05:55.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":123,"price":47.32,"value":5820.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.1591 to $47.5081, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":53215,"source":{"system":"sec-edgar","filing":"0001209191-23-012001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123012001/doc4.xml","form_type":"4"}},{"id":1998806,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-22T20:05:55.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":3140,"price":46.61,"value":146355.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.1267 to $47.1224, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":53338,"source":{"system":"sec-edgar","filing":"0001209191-23-012001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123012001/doc4.xml","form_type":"4"}},{"id":1998805,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-22T20:05:55.000Z","date":"2023-02-18","kind":"exercise","acquired":true,"shares":11139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":56478,"source":{"system":"sec-edgar","filing":"0001209191-23-012001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919123012001/doc4.xml","form_type":"4"}},{"id":2300020,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-08T18:56:51.000Z","date":"2022-04-08","kind":"exercise","acquired":false,"shares":86348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-07","underlying":"Common Stock","underlying_shares":86348},"source":{"system":"sec-edgar","filing":"0001209191-22-023901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122023901/doc4.xml","form_type":"4"}},{"id":2300019,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-08T18:56:51.000Z","date":"2022-04-08","kind":"sale","acquired":false,"shares":14885,"price":65.14,"value":969608.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.93 to $65.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-22-023901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122023901/doc4.xml","form_type":"4"}},{"id":2300018,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-08T18:56:51.000Z","date":"2022-04-08","kind":"sale","acquired":false,"shares":53987,"price":64.42,"value":3477842.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.93 to $64.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":60224,"source":{"system":"sec-edgar","filing":"0001209191-22-023901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122023901/doc4.xml","form_type":"4"}},{"id":2300017,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-08T18:56:51.000Z","date":"2022-04-08","kind":"sale","acquired":false,"shares":17476,"price":63.55,"value":1110599.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.93 to $63.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":114211,"source":{"system":"sec-edgar","filing":"0001209191-22-023901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122023901/doc4.xml","form_type":"4"}},{"id":2300016,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-08T18:56:51.000Z","date":"2022-04-08","kind":"exercise","acquired":true,"shares":86348,"price":12.73,"value":1099210.04,"ownership":{"direct":true},"balance_after":131687,"source":{"system":"sec-edgar","filing":"0001209191-22-023901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122023901/doc4.xml","form_type":"4"}},{"id":2334923,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-14T16:13:45.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":22034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":22034,"derivative":{"underlying":"Common Stock","underlying_shares":22034},"source":{"system":"sec-edgar","filing":"0001209191-22-018450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122018450/doc4.xml","form_type":"4"}},{"id":2334922,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-14T16:13:45.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":17916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 10, 2022, the reporting person was granted options to purchase 17,916 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":17916,"derivative":{"exercise_price":56.73,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":17916},"source":{"system":"sec-edgar","filing":"0001209191-22-018450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122018450/doc4.xml","form_type":"4"}},{"id":2371445,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-25T19:08:36.000Z","date":"2022-02-23","kind":"exercise","acquired":false,"shares":7906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":15813,"derivative":{"underlying":"Common Stock","underlying_shares":7906},"source":{"system":"sec-edgar","filing":"0001209191-22-013359","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122013359/doc4.xml","form_type":"4"}},{"id":2371444,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-25T19:08:36.000Z","date":"2022-02-24","kind":"sale","acquired":false,"shares":1371,"price":51.33,"value":70373.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.92 to $51.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-22-013359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122013359/doc4.xml","form_type":"4"}},{"id":2371443,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-25T19:08:36.000Z","date":"2022-02-24","kind":"sale","acquired":false,"shares":3875,"price":52.03,"value":201616.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.60 to $52.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":46710,"source":{"system":"sec-edgar","filing":"0001209191-22-013359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122013359/doc4.xml","form_type":"4"}},{"id":2371442,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-25T19:08:36.000Z","date":"2022-02-24","kind":"sale","acquired":false,"shares":2660,"price":52.94,"value":140820.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.61 to $53.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":50585,"source":{"system":"sec-edgar","filing":"0001209191-22-013359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122013359/doc4.xml","form_type":"4"}},{"id":2371441,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-25T19:08:36.000Z","date":"2022-02-23","kind":"exercise","acquired":true,"shares":7906,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":53245,"source":{"system":"sec-edgar","filing":"0001209191-22-013359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122013359/doc4.xml","form_type":"4"}},{"id":2377449,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-23T19:07:02.000Z","date":"2022-02-18","kind":"exercise","acquired":false,"shares":11139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":11139,"derivative":{"underlying":"Common Stock","underlying_shares":11139},"source":{"system":"sec-edgar","filing":"0001209191-22-012394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122012394/doc4.xml","form_type":"4"}},{"id":2377448,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-23T19:07:02.000Z","date":"2022-02-22","kind":"sale","acquired":false,"shares":4607,"price":54.84,"value":252647.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.46 to $55.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-22-012394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122012394/doc4.xml","form_type":"4"}},{"id":2377447,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-23T19:07:02.000Z","date":"2022-02-22","kind":"sale","acquired":false,"shares":6532,"price":55.6,"value":363179.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.23 to $56.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":49946,"source":{"system":"sec-edgar","filing":"0001209191-22-012394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122012394/doc4.xml","form_type":"4"}},{"id":2377446,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-23T19:07:02.000Z","date":"2022-02-18","kind":"exercise","acquired":true,"shares":11139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":56478,"source":{"system":"sec-edgar","filing":"0001209191-22-012394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122012394/doc4.xml","form_type":"4"}},{"id":2437436,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-11T20:06:57.000Z","date":"2022-01-08","kind":"exercise","acquired":false,"shares":20948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On January 8, 2019, the reporting person was granted 62,843 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On January 8, 2019, the reporting person was granted 62,843 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20948},"source":{"system":"sec-edgar","filing":"0001209191-22-002991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122002991/doc4.xml","form_type":"4"}},{"id":2437435,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T20:06:57.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":4252,"price":40.09,"value":170462.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.60 to $40.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-22-002991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122002991/doc4.xml","form_type":"4"}},{"id":2437434,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T20:06:57.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":13935,"price":40.8,"value":568548.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.36 to $41.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":49591,"source":{"system":"sec-edgar","filing":"0001209191-22-002991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122002991/doc4.xml","form_type":"4"}},{"id":2437433,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T20:06:57.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":2761,"price":41.74,"value":115244.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.37 to $42.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":63526,"source":{"system":"sec-edgar","filing":"0001209191-22-002991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122002991/doc4.xml","form_type":"4"}},{"id":2437432,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T20:06:57.000Z","date":"2022-01-08","kind":"exercise","acquired":true,"shares":20948,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":66287,"source":{"system":"sec-edgar","filing":"0001209191-22-002991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919122002991/doc4.xml","form_type":"4"}},{"id":2538834,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-19T16:26:02.000Z","date":"2021-10-15","kind":"exercise","acquired":false,"shares":13448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units vest as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units vest as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13448},"source":{"system":"sec-edgar","filing":"0001209191-21-060907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121060907/doc4.xml","form_type":"4"}},{"id":2538833,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-19T16:26:02.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":500,"price":38.88,"value":19440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. A substantial portion of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.60 to $39.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45339,"source":{"system":"sec-edgar","filing":"0001209191-21-060907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121060907/doc4.xml","form_type":"4"}},{"id":2538832,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-19T16:26:02.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":1958,"price":39.44,"value":77223.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. A substantial portion of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":45839,"source":{"system":"sec-edgar","filing":"0001209191-21-060907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121060907/doc4.xml","form_type":"4"}},{"id":2538831,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-19T16:26:02.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":4288,"price":40.77,"value":174821.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. A substantial portion of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.34 to $41.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":47797,"source":{"system":"sec-edgar","filing":"0001209191-21-060907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121060907/doc4.xml","form_type":"4"}},{"id":2538830,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-19T16:26:02.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":6702,"price":41.49,"value":278065.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. A substantial portion of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $42.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":52085,"source":{"system":"sec-edgar","filing":"0001209191-21-060907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121060907/doc4.xml","form_type":"4"}},{"id":2538829,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-19T16:26:02.000Z","date":"2021-10-15","kind":"exercise","acquired":true,"shares":13448,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":58787,"source":{"system":"sec-edgar","filing":"0001209191-21-060907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121060907/doc4.xml","form_type":"4"}},{"id":2831970,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-25T16:24:38.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":23719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":23719,"derivative":{"underlying":"Common Stock","underlying_shares":23719},"source":{"system":"sec-edgar","filing":"0001209191-21-014318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121014318/doc4.xml","form_type":"4"}},{"id":2831969,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-25T16:24:38.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":18714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 23, 2021, the reporting person was granted options to purchase 18,714 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":18714,"derivative":{"exercise_price":36.89,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":18714},"source":{"system":"sec-edgar","filing":"0001209191-21-014318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121014318/doc4.xml","form_type":"4"}},{"id":2842703,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":67551,"kind":"person","name":"Neumann Mark","position":1,"cik":"0001756211","reported_name":"Neumann Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-22T20:07:41.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":11139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":22278,"derivative":{"underlying":"Common Stock","underlying_shares":11139},"source":{"system":"sec-edgar","filing":"0001209191-21-012958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000120919121012958/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-22T20:07:41.000000Z,2842703"}